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Abstract
In late December 2019, a cluster of atypical pneumonia cases was noticed in Wuhan, China,
which was later identified as an outbreak of coronavirus disease 2019 (COVID‐19). Since then, it
has spread globally, causing public health emergency and urgency, and declared as a pandemic by
the World Health Organization (WHO). As of 1 April 2020, the data shows more than 200 countries
and territories have been affected, with more than 824,000 confirmed cases and 41,000 deaths.
Across the globe, many cancer patients visit the hospital and clinics for treatment and investigations.
A large number of this population are immunocompromised, either due to their underlying disease
or cancer treatments which put them at higher risk for infection and complications. In addition, several risk factors have been identified that increase the risk and severity of infection with COVID-19,
and cancer patients commonly have many of them. Recently, a large retrospective study among cancer patients infected with COVID-19 in Wuhan, China, found a higher incidence of severe events in
cancer patients compared to patients without cancer. As doctors working amid this pandemic, we all
have responsibilities and duties to act upon local guidelines to ensure the continuation of essential
cancer services without overwhelming the health care system. In this review, we addressed the potential challenges and possible actions for clinicians to manage cancer patients during this unusual
time.
Keywords: COVID‐19, Cancer, Coronavirus disease 2019, Management, Recommendations.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the name given
to describe the first cases infected with coronavirus 2 in Wuhan, China, which lead to
coronavirus disease 2019 (COVID- 19) [1].
The zoonotic coronaviruses family has previously caused two outbreaks, the first was in
2002-2003 and called severe acute respiratory
syndrome (SARS) and the second was the
Middle East respiratory syndrome (MERS) in
2012 [2]. The novel coronavirus disease
(COVID-19) has easy transmission between
humans by contact with the droplets of infected persons through respiratory secretions
or contaminated materials, and its clinical
course can range from asymptomatic (silent
carrier) or mild infection to severe respiratory

failure [1, 3]. The death rate from the coronavirus varies widely between countries. As of
the end of March 2020, data showed the global
death rate ranging from 0.8% to 15.7%; this
largely depended on the country’s health-care
system, testing capacity and the characteristics
of the population [4]. Case fatality rate or
death rate is also markedly higher in people
with comorbidities like hypertension, diabetes
mellitus, cardiovascular disease and respiratory issues [4]. Therefore, it was extremely essential for all countries to implement early
strict safety measures, in order to limit its
transmission worldwide and prevent a global
catastrophe.
Several researches and reviews have been
conducting globally to present the challenges
that cancer patients face during the COVID-
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19 pandemic and guide their management
from diagnosis to the point of complete recovery or palliation [5-18]. Some of these focused
on specific cancer types (such as lung cancer)
or specific phase of cancer treatment whereas
other guidelines suggested general recommendations for managing cancer patients [5-7, 912, 15-18]. In Palestine, guidelines for handling urological surgeries during the COVID19 pandemic were recently published with
collaboration of regional team [19]. Other
Recommendations were also released for safe
and effective practice of interventional cardiology during the COVID-19 pandemic [20].
Furthermore, the Palestinian ministry of
health published a national protocol to deal
with the COVID-19 pandemic and manage the
infected cases [21]. Among these guidelines,
there is no definite recommendations for handling cancer patients during the COVID-19
pandemic in Palestine.
During this global pandemic, the cancer
population faces many difficulties and unanswered questions about their health situation.
Additionally, the pandemic will require
health-care workers to make difficult decisions, including inventing prioritization criteria for treatment. For cancer patients, the possibility of gaining benefit from their treatment
may outweigh the risk of death from this virus.
For that, we will discuss first the risk of getting infected with COVID-19 among this
community according to the latest research
done. Then, we will try to manage every step
involved in their treatment, rather than definitive guidance, taking into consideration the
safety measures among endemic area of
COVID-19.
Cancer patients are a high risk population
Cancer affects a large number of people
worldwide. In 2018, 17 million new cases
were diagnosed with cancer globally, and
there will be 27.5 million new cases of cancer
each year by 2040 [22]. The current pandemic
has put the health of cancer patients at risk, as
many of them will need to leave their home to
seek help from hospitals for treatment or acute
events. In addition, cancer treatment per se is
a predisposing factor for infections like
COVID-19, as it blunts the immune status, decreases immunosuppressive cytokines, and increases pro-inflammatory signals similar to

what is believed to happen in COVID-19 [23].
At first, Liang et al in China described how
COVID-19 outcomes varied between cancer
and non-cancer patients. They found that cancer as a comorbidity was associated with increased risk of death and intensive care units’
admission. However, data could not be generalized because the sample size was very small,
as the report included data from only 18 cancer patients [24]. In another study, which was
also in China and a little larger in sample size
than the previous study, 28 cancer patients
with laboratory-confirmed COVID-19 were
described. 53.6% of the patients developed severe events, 21.4% were admitted to ICU,
35.7% had life-threatening complications, and
28.6% of the patients died [24]. Another study
was done in China with a larger sample size,
involving 105 hospitalized patients with cancer and 233 patients without cancer. In this
study, COVID-19 patients with cancer compared to COVID-19 patients without cancer
had more severe outcomes, particularly patients with blood cancer, lung cancer, and cancers in metastatic stages [8]. Research has also
been underway in Europe, particularly in Italy,
which has been badly hit by COVID-19. In Italy, analysis of a sample of 355 out of 2003
who died (17.7%) showed 72 patients (20.3%)
had history of active cancer concurrent to
COVID-19 infection. Furthermore, a high percentage of those who died had underlying diseases that could have increased their risk of
death independently of the infection. Of all patients who died, 117 (30%) had ischemic heart
disease, 126 (35.5%) had diabetes, 72 (20.3%)
had cancer, 87 (24.5%) had atrial fibrillation,
24 (6.8%) had dementia, and 34 (9.6%) had
had a stroke [25]. Regarding case fatality rate,
up until February 20, 2020, the case fatality
rate for patients with cancer as a comorbidity
in COVID-19 infection in China was 7.6%,
compared to 13.2% for those with cardiovascular disease, 9.2% for diabetes, 8.4% for hypertension, and 8.0% for chronic respiratory
disease. Meanwhile the overall death rate was
3.8%, and the case fatality rate for those who
reported no comorbid conditions was 1.4%
[3].
COVID-19 represents a major threat to
cancer patients’ lives, in terms of pathophysiology as well as the circumstances that sur-
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round social distancing measures, e.g., the disruption of the routine health-care system.
Thus, clinicians, nurses and other health-care
providers should attempt to provide the required care, with referral to a local guideline.
Challenges during COVID-29 pandemic
When the WHO declared COVID-19 a
pandemic, hospitals started to reorganize their
wards and activities to deal with the increasing
number of COVID-19 patients that required
admission [26]. Moreover, the threat posed by
the rapidity of disease dissemination that
could overwhelm health-care facilities, compounded by potential infection of the medical
staff with COVID-19, in addition to quarantine, travelling-bans, and resource constraints
disrupting supply chains, all may mandate prioritization or modification of patients’ cancer
therapies. Thus, the oncology community may
be forced towards selection of patients who
should receive anti-cancer treatment based on
the clinical data on who will get the most benefit [27]. Oncologists and hematologists will
have to weigh the risk of developing COVID19 in severely immunosuppressed patients
against the risk of disease progression, taking
into consideration the health-care services’
conditions and shortages of medical supply.
The clinical presentations of COVID-19
are varied, ranging from asymptomatic and
mild, to severe pneumonia and ARDS. Therefore, the diagnosis of this novel infection
could be challenging in patients with cancer,
particularly in those with lung cancer or those
who developed pneumonitis due to anti-cancer therapy. Moreover, radiological manifestations of COVID-19 are not specific and
could be shared with other types of infections
and inflammatory processes [14, 28-34].
With this complexity, it is reasonable to
suggest that patients with cancer, particularly
lung cancer, should undergo testing for
COVID-19 whenever they have any clinical
symptoms suggestive of infection. Furthermore, with the clinical aggressiveness observed in lung cancer, therapy may not be
postponed [14].
Searching the right approach, from outpatient to inpatient management:
Responses and actions are evolving rapidly throughout the COVID-19 pandemic.

Hemato-oncologists should follow the guidelines and latest updates recommended by the
Ministry of Health, and most importantly, engaging them in their plans.
At a time in which the risk of COVID-19
infections is high and there is a burden on the
health-care system and an inability to deliver
the routine care, actions should be taken according to the presence or absence of threat by
COVID-19 locally [11, 17].
-Information for patients
The impact of the COVID-19 pandemic
on cancer patients and their families is huge
and distressing. Oncologists and hematologists should clearly explain to cancer patients
their vulnerability to getting the infection, the
consequences of this global pandemic on their
health, and the risks of therapy modifications.
In addition, telemedicine (including phone
calls and internet-based communications)
should be used to contact patients or their
caregivers regarding home-administration of
treatment, counseling, adverse effects of medications, or other medical issues that may arise
[10].
-Outpatient care
Given the susceptibility of patients with
cancer to SARS-CoV-2 infection, their presence at hospitals should be minimised [35].
Certain measures should be taken to encourage cancer patients to stay at home if applicable and teach them how to protect themselves
while they are at home with their families.
Cancer patients who have close family
members with confirmed or suspected
COVID-19 infection should always be isolated away from these members and should
contact their clinician for further engagement
in the steps necessary to reduce the possibility
of being infected by COVID-19. In the same
way, clinicians should inform these patients
about the symptoms of this disease and when
and how to seek medical advice, emphasizing
the importance of contacting their primary clinician just before going to the emergency department and having the assessment done in an
isolated room. The medical staff must take a
comprehensive medical history from the patients and work according to the latest guidelines. Also, medical staff must keep in mind
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the wide differential diagnosis of fever in cancer patients, including drug-related fever, bacterial infections, fungal infections or viral infections which are not limited to COVID-19
[36].
Health-care systems and clinicians must
be aware that certain measures should be implemented in diagnosing cancer patients during this pandemic. For example, assessment of
COVID-19 infection should not be done in
communal places where suspected cancer patients are gathered with others in one place.
For patients who have met the scoring system
criteria for COVID-19 (Table 1), testing
should be done, while lung cancer patients
who have fever or any new respiratory symptoms have to be tested regardless of the scoring systems [14]. During this pandemic, cancer patients should inform their health-care
providers about their clinical history, as well
as have their primary clinician’s phone number at hand for continuous updates about their
clinical status.
Table (1): Indicators for COVID-19 infection.
Indicator
Fever above 38.5 C
Sever or progressive
dry cough
Influenza symptoms
(runny nose, sore
throat)
Recent travel within
14 days to an infected area or close
contact with a person returning from
travel
Close contact with a
confirmed case
A family member or
friend having influenza, dry cough or
fever
Health-care workers

Point*
1
1
1

2

3
1

1

* COVID-19 infection suspicion score is calculated by summation of total points beside each
indicator; if the total points are less than 3: low
possibility, 3-5: suspected, above 5: highly suspected.

For outpatient care management, healthcare workers are advised to do phone calls

with cancer patients planned to present to the
hospital the next day, in order to ensure these
patients do not have symptoms compatible
with COVID-19 infection. In outpatient clinic,
chemotherapy centers should be open-space,
have mobile walls between seats, and all patients and staff must wear face masks [11, 35].
The risk of transmitting COVID-19 could
be decreased through infection control policies applied in the hospital. It is mandatory for
all staff in a health institution to be screened at
every entry to the hospital, as well as designing the flow of patients to minimize contact
between them.
Controlling and evaluating COVID-19 infection during hospitalization
Hospital admission for the vast majority
of cancer patients is an indispensable step in
the oncology treatment path. It is necessary for
managing chemotherapy complications, monitoring disease progression and administration
of aggressive therapy for some cancer types
(such as hematologic malignancies, in which
close observation of patients during active
therapy is mandatory) [37]. The concern is
more substantial if the patients are elderly or
have multiple medical conditions which require greater attention [38]. A previous cohort
analysis described the characteristics of admitted cancer patients and the reasons for admission [37]. The results showed that the median hospitalization time was 9 days and patients with lung cancer were the second most
frequently admitted patients [37]. Moreover,
cancer therapy and diagnosis were found to
form about 20% of hospital admissions,
whereas the rest of admissions were due to uncontrolled symptoms [37].
In hospital, the appropriate methods for
managing the COVID-19 pandemic are limiting the number of hospital entry points and restricting emergency visits for urgent cases.
These can be achieved by deploying a triage
tent at the main emergency entrance for evaluating the emergent of hospital visits. Also, at
each entry point, full assessment regarding
COVID-19 infection suspicion and indicators
for all patients, visitors, health-care professionals and other workers should be safely applied (Table 1). After that, suspected cases of
COVID-19 infection must be properly isolated and tested for confirmation. If the
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COVID-19 PCR test is positive then the patient has to be handled according to the CDC
and WHO updated guidelines [39, 40]. In case
of precluding the infection, assessment of the

need for quarantine should be undertaken, especially if the patient has recently been exposed to a confirmed infected case, or his/her
COVID-19 infection suspicion score is equal
or above 3 (Figure 1).

Figure (1): Scheme for cancer patients’ hospitalization process. CBC: complete blood count, CT:
computed tomography.
of neutropenia for many of them [44]. The epAnti-cancer treatment during COVID-19
idemic analysis in China showed that patients
pandemic: strategies and recommendations
who were recently exposed to chemotherapeuAs reported in many studies, patients with
tic agents or procedures are at greater risk for
hematologic or non-hematologic malignansevere illness with COVID-19 [42]. This is in
cies are at high risk for infection with novel
addition to the disease process itself, such as
coronavirus disease (COVID-19) as well as
leukemia and multiple myeloma, that can imother infections [24, 41-43]. These patients
pair immune system functions [45].
may also have worse clinical outcomes if they
Furthermore, numerous cancer patients
get infected with COVID-19 compared to
use other immunosuppressive agents such as
those who have no comorbid conditions [42].
corticosteroids, which are part of some chemA recent analysis in China reported that thirtyotherapy regimens and are frequently given as
nine percent of oncology patients with
premedication. These corticosteroids will inCOVID-19 died or were entered into the criticrease the risk of infections, including infeccal care unit [42]. Specifically, it seems that
tion of the lower respiratory system [46, 47].
COVID-19 attacks patients with lung cancer
Therefore, it is important to use the lowest
more prominently than other malignancies,
possible therapeutic dose with minimal durawhich necessitates additional strict measures
tion, and to be given once a day in the mornin these patients [24].
ing, or dosed every other day if applicable, to
A reason behind that is the cytotoxic medreduce corticosteroid adverse effects [48].
ications that are given to cancer patients,
which cause immunosuppression in the form
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Our goals are to decrease the exposure of
cancer patients to hospitals and clinics and
maintain the functioning of their immune system whenever possible. These goals can be
achieved by composing effective strategies
and developing polices to cope with this pandemic according to the local means and availability of materials.
One of the suggested strategies to decrease the risk of neutropenia in cancer patients is to give prophylactic granulocyte colony stimulating factor (G-CSF), especially
when the chemotherapy session can’t be delayed or cytotoxic drugs’ dose should not be
reduced [49]. Indeed, one may consider administering prophylactic G-CSF with chemotherapy protocols that are associated with febrile neutropenia in 10-20% of patients, taking
into consideration other factors such as health
cost burden and adverse effects of G-CSF [49,
50].
Another strategy is to postpone the initiation of the chemotherapy phase (especially in
the adjuvant setting) in newly diagnosed patients for an acceptable period of time and
without affecting the desired outcomes [42].
For example, in patients with stage I, II, and
III breast cancer, adjuvant chemotherapy regimens can be deferred up to 90 days after surgery without influencing the overall survival,
but more than 90 days of deferral is not advisable [51, 52].
Choosing alternative chemotherapy protocols with similar efficacy is one of the most
powerful strategies to cope with global shortages of chemotherapeutic medications [53].
This strategy can also be used wisely to overcome the increased hospital visits and contact
time with health-care professionals required
due to frequent dosing of some chemotherapy
protocols. For example, in platinum-resistant
recurrent epithelial ovarian cancer, administration of doxorubicin in its liposomal formulation every 28 days could be chosen instead of topotecan (given in the first 5 days of
each 21 days cycle), considering both regimens have the same therapeutic outcomes
with regard to survival and response [54, 55].
Another way to deal with the COVID-19
pandemic in oncology patients is to administer
cytotoxic medications at home. This can re-

duce the need for hospital admissions and subsequently prevent hospital-related infections.
For example, using a disposable pump at
home to deliver fluorouracil (which is a part
of FOLFOX and FOLFIRI protocols) in place
of continuous infusion at hospital in patients
with colorectal cancer [56].
Choosing the appropriate route of administration for chemotherapeutic agents without
compromising the desired goals should also be
considered. In practice, we can use a per os
capecitabine-based regimen for rectal cancer
and other gastrointestinal malignancies with
intent to cure the disease instead of fluorouracil infusion [57]. In addition, subcutaneous
bortezomib for patients with multiple myeloma can be safely administered at home,
which has comparable efficacy to intravenous
bortezomib [58, 59].
Finally, confirmed or suspected cases of
COVID-19 among cancer patients should immediately be withheld from chemotherapy,
and resume it later after achieving a full recovery from infection according to the patient’s
clinical status and laboratory tests [5].
Table 2 summarizes the strategies for
cancer patients with active anti-cancer treatment during the COVID-19 pandemic.
Table (2): Summary of the strategies for cancer patients with active anti-cancer treatment
during COVID-19 pandemic.
Suggested ways to decrease the risk of
COVID-19 infection in cancer patient
during active anti-cancer treatment.
*Suggesting prophylactic G-CSF.
*Delaying anticancer therapy if appropriate.
*Using alternative therapeutic options.
*Delivering chemotherapy at home.
* Using alternative routes of administration.
Guidance to cope with global shortages of
anti-cancer drugs
Oncology departments in healthcare institutions should prepare short-term and longterm plans to face the global shortages of
chemotherapeutic medications and personal
protective equipment (PPE). Chemotherapeutic medications took the lead among medication shortages in 2010, and the Food and Drug
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Administration is continuously updating the
drug shortages status [60, 61]. The shortages
in the supply of cytotoxic medications require
local oncology departments, in collaboration
with health-care professionals (doctors, pharmacists and nurses), to utilize alternative therapeutic options, use substitutional chemotherapy protocols, and prioritize patients with high
risk diseases [62]. These strategies can be applied in some cases. But, in other cases, delaying chemotherapy sessions, administering insufficient doses, or using substitutional regimes are not appropriate and may have a negative impact on patients’ lives [63, 64], i.e. the
drug, cytosine arabinoside (Ara-C) is considered as a mainstay of therapy in patients with
acute myelogeneous leukemia [65].
Therefore, institutions should have information about causes beyond the lack of supply
and the time period of medication shortages by
maintaining continuous contact with suppliers
and manufacturers, to be able to make strategic steps towards addressing this problem [5,
53]. Also, oncology departments should thoroughly analyze the availability of medications
(especially currently scarce medications and
medications that possibly will be in shortages)
in its pharmacy stocks and for how long the
current inventory will last [53]. Furthermore,
collaboration between local oncology departments to cover the gap of short supply should
be attempted [53].
In pharmacy departments, following the
instructions regarding chemotherapeutic products’ stability after dilution or opening of vials
should be taken into consideration. Some
products may have a longer stability time
when they are diluted at different concentrations (such as etoposide) or stored at different
temperatures [66]. For example, the vial stability of asparaginase E.coli after reconstitution is 3 hours at room temperature compared
to 72 hours if the vial stored in a refrigerator
[66]. On the other hand, some products may
have a short-time stability and the remaining
vial content must be discarded after opening
[66]. Therefore, following products’ stability
guidance can help preserve the remaining vial
content and share it between patients whenever possible by arranging dates for patient’s
attendance to their sessions taking into consideration infection control protocols during
chemotherapy preparation.

Treating cancer patients with COVID-19
infection
Many studies have established the risk
factors associated with increased mortality
rate in COVID-19 patients. Of those, age, a
higher sequential organ failure assessment
(SOFA) score and comorbidities appear to
have significant effect [67-69]. However,
some laboratory findings linked with adverse
outcomes in COVID-19 patients are usually
present in patients with cancer, such as lymphopenia, high D-dimer and lactate dehydrogenase, thus the interpretation of these findings in cancer patients should be done with
caution [69-71]. Nevertheless, the published
data about oncology patients infected with
COVID-19 showed a higher incidence of
complications including ICU admission, invasive ventilation and death [24].
Besides age and comorbidities, the cancer
patients most vulnerable for the development
of complications are patients who receive active chemotherapy, immunotherapy or radiotherapy for lung cancer, in addition to patients
who have had bone marrow transplants within
the last 6 months, or who are still taking immunosuppressive drugs [6, 72]. Nonetheless,
criteria for hospitalization should still be followed. In patients with those additional risk
factors, the prognosis appears worrisome, and
frank discussions with the patients and their
families should be done thoroughly [11]. On
the other hand, in cancer patients with no active disease, and who are no longer on immunosuppression therapy, the regimen to treat
COVID-19 should be followed as the general
population [7].
Treating cancer patients with COVID-19
should be individualized, and depends on the
above-mentioned characteristics. Cancer patients with COVID-19 should be transferred to
a COVID-19 admission area, while the main
oncology department should not admit any
case of COVID-19 if possible [10].
Special considerations
Transfusion considerations
Shortages of blood products will arise
during the pandemic from constraints on
health-care capacities as a result of the influx
of COVID-19 patients to the hospital and the
societal effects on donation. The optimal
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threshold for outpatients’ transfusion of patients with haematological malignancies has
not been established yet [73]. On the contrary,
restriction of transfusion may be inappropriate
in patients with cardiovascular disease [74].
However, erythropoietin, folic acid, iron and
vitamin B12 may serve as an appropriate substitute that should be considered to limit transfusion requirements.
Shortages of platelet products will be noticed early on, as platelets have the shortest
half-life among blood cells. According to the
latest guidelines, there is no rule to transfuse
platelets prophylactically in asymptomatic patients with chronic bone marrow failure or for
clinically stable patients without bleeding after autologous bone marrow transplantation
[75].
Overall, during the threat of shortages in
blood products, clinicians have to consider
those at highest risk of bleeding and red cell
requirements, and provide alternative solutions as deemed appropriate. Also, the facility
has to preserve sufficient levels of donation of
blood products by encouraging the population
to donate and preparing safety steps to reduce
donors’ contact time outside the home. This
may be accomplished by using telecommunication to arrange the donation time. Additionally, the workers in their health-care institutions themselves can be considered for donation [5].
Surgery for cancer patients
During the current pandemic, hospitals
are facing difficult decisions on how to reallocate its resources, beds, ICU capacities, blood
products and the needed PPE. Although nothing can replace judgments on the ground, it
has been generally advised to avoid all unnecessary surgeries. The intention behind that is
to help institutions where community spread
of COVID-19 is deemed high [41, 76]
Along those lines, elective surgeries that
pose a high chance of long postoperative ICU
admission and utilization of ventilators are advised to be delayed. Such cases need to be
evaluated on a regular basis based on local circumstances, and the availability of non-surgical therapies [41].

Multidisciplinary team discussion is
highly recommended for non-urgent surgeries, and patients should be informed about the
pros and cons depending on local resources,
tumor characteristics and expected outcomes
upon delay. However, the extent of this delay
could vary depending on the current threat by
the infection.
Bone marrow transplant (BMT) in cancer
patients
Patients who are undergoing bone marrow transplantation will be at greater risk of
infections during and after transplantation
[77]. Of these, lower respiratory tract infections are considered one of the most common
infections among these patients, including viral infections [78].
In BMT patients, neutropenia will last
about 5-30 days after transplantation, which
requires the BMT unit to follow strict
measures in an attempt to decrease infection
risk and keep the environment clean by fully
adhering to standard infection control principles and regulations [79, 80]. Moreover, nonmyeloablative conditioning regimens could be
used to minimize the duration of neutropenia
[79].
Clinical assessment, history taking, and
laboratory tests (including tests for respiratory
viral infections) should be done, and in the
case of confirmed respiratory tract infections
before BMT, treated accordingly [81]. Cases
with COVID-19 infection should be isolated
in a separated room with neutral environmental pressure. The BMT should be delayed for
90 days if the patient presented with low-risk
disease, or until the COVID-19 PCR test is
negative for three consecutive weeks with
complete resolution of symptoms for high-risk
disease [9]. BMT should also be postponed for
2-3 weeks (from the last contact) in case of
contact with COVID-19 patients, and frequent
laboratory tests for monitoring COVID-19 infection are recommended [9].
CONCLUSIONS
Until now, there is no definitive treatment
for COVID-19, which has been spreading rapidly worldwide since the beginning of 2020,
with variations in the rates of mortality and infection between countries. This may be due to
factors like infection control measures taken,
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health-care system capacity, early preparation
and implementation of guidelines and the biological structure of populations, which may
differ between continents and even countries.
Many researchers reported an increased
risk of COVID-19 infection among cancer patients and noted a higher mortality rate compared to the public [24, 41, 42]. Cancer services are not on the frontline of the coronavirus pandemic, but do have a major role to
play, and this must be well-planned. In response to the pressures on the health-care system, the expected lack of adequate health-care
infrastructure and human resources, supply
disruption and fear among patients and healthcare workers, the elective component of our
work may be lessened. However, cancer services will need to continue to deliver care.
Therefore, we should seek the best local solutions to continue offering proper management,
while protecting resources, patients and staff.
In this article and based on the latest clinical
research, we discussed the risk of getting infected with COVID-19 among cancer patients,
and we tried to manage every step involved in
their treatment, rather than offering definitive
guidance, taking into consideration the safety
measures among endemic areas of COVID19. The general recommendations for cancer
patients during COVID-19 pandemic as following. First, it is imperative for competent
authorities to take proactive steps in increasing the general health awareness about the risk
of COVID-19 infection in cancer patients, and
implementing rules that would decrease the
risk of its transmission. Second, clinicians
should explain honestly to cancer patients the
risk of COVID-19 infection versus the risks of
treatment modifications. Also, health-care
providers have to continuously stay up to date
with the newest information about COVID-19
infection in cancer patients and recommendations. Third, health-care institutions (including oncology departments) should follow a
comprehensive guidance plan to face this pandemic, focusing on the creation of local guidelines, as the epidemic status and the local possibilities may significantly differ between different areas. Finally, extreme precautions
should be taken for cancer patients in case of
easing the lockdown and reopening businesses
by following strict infection control measures.
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